Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Retained Earnings: 2023-2024

Historic Retained Earnings for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to -$106.1 million.

  • Inhibrx Biosciences' Retained Earnings fell 266.04% to -$213.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$213.4 million, marking a year-over-year decrease of 266.04%. This contributed to the annual value of -$106.1 million for FY2024, which is 82.71% up from last year.
  • Per Inhibrx Biosciences' latest filing, its Retained Earnings stood at -$106.1 million for FY2024, which was up 82.71% from -$613.7 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Retained Earnings ranged from a high of -$106.1 million in FY2024 and a low of -$613.7 million during FY2023.
  • Its 2-year average for Retained Earnings is -$359.9 million, with a median of -$359.9 million in 2023.
  • Data for Inhibrx Biosciences' Retained Earnings shows a peak YoY soared of 82.71% (in 2024) over the last 5 years.
  • Inhibrx Biosciences' Retained Earnings (Yearly) stood at -$613.7 million in 2023, then spiked by 82.71% to -$106.1 million in 2024.